Distributed and On-demand Production of Magistral Biotherapeutics and At-home Biosensors from Shelf-stable Cost-effective Reagents

Lecture / Panel
For NYU Community



Bradley Bundy

Department of Chemical Engineering
Brigham Young University



In-vitro “Cell-free” Protein Synthesis systems hold immense disruptive potential within the protein pharmaceutical and medical diagnostics industries. Recent engineering advancements have paved the way for the on-demand production of biotherapeutics, both at the point-of-care and in the comfort of one's home. This capability is vital in facilitating magistral and personalized treatments, disrupting the way we approach healthcare. Furthermore, notable progress has been made in the development of “Cell-free” at-home colorimetric biosensors, opening up new possibilities for personalized cancer treatment. These innovations have the potential to enhance survival rates for acute lymphoblastic leukemia by 10%.


Dr. Brad Bundy is a Professor of Chemical Engineering at Brigham Young University and the PI of the Bundy Biotechnology Lab which performs research in cell-free synthetic biology with four key objectives:
1) Engineer More Effective Biotherapeutics through location-optimized PEGylation;
2) Enable Personalized Cancer Treatment with low-cost, at-home biosensors;
3) Develop On-Demand Magistral Production of Biologics with lyophilized cell-free protein
4) Build Better Biocatalysts through orientation-controlled covalent immobilization
Professor Bundy is the recipient of the NSF CAREER Award, DARPA Young Faculty Award, BYU Young Scholar Award, and Chemical Engineering Research Professorship. Dr. Bundy is committed to excellence in education and is the recipient of University, College, Department, and Student-voted Teaching Awards.